[{"id":"2f22aa18-755d-413d-9da7-9cb6d892af4b","acronym":"TRITON3","url":"https://clinicaltrials.gov/study/NCT02975934","created_at":"2021-01-18T14:37:50.152Z","updated_at":"2024-07-02T16:35:13.638Z","phase":"Phase 3","brief_title":"A Study of Rucaparib Versus Physician's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency","source_id_and_acronym":"NCT02975934 - TRITON3","lead_sponsor":"pharmaand GmbH","biomarkers":" BRCA1 • BRCA2 • ATM • BRCA","pipe":" | ","alterations":" BRCA2 mutation • BRCA1 mutation • ATM mutation • BRCA1 mutation + ATM mutation","tags":["BRCA1 • BRCA2 • ATM • BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA2 mutation • BRCA1 mutation • ATM mutation • BRCA1 mutation + ATM mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e docetaxel • Xtandi (enzalutamide) • Rubraca (rucaparib) • abiraterone acetate"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 405","initiation":"Initiation: 06/13/2017","start_date":" 06/13/2017","primary_txt":" Primary completion: 08/25/2022","primary_completion_date":" 08/25/2022","study_txt":" Completion: 12/01/2024","study_completion_date":" 12/01/2024","last_update_posted":"2024-03-20"},{"id":"33e6efe3-69ef-47f0-b007-a45c428903e9","acronym":"TRITON2","url":"https://clinicaltrials.gov/study/NCT02952534","created_at":"2021-01-17T17:39:04.239Z","updated_at":"2024-07-02T16:35:46.027Z","phase":"Phase 2","brief_title":"A Study of Rucaparib in Patients With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency","source_id_and_acronym":"NCT02952534 - TRITON2","lead_sponsor":"zr Pharma \u0026 GmbH","biomarkers":" BRCA1 • BRCA2 • HRD","pipe":" | ","alterations":" BRCA2 mutation • BRCA1 mutation • HRD • ATM mutation • HRD + BRCA1 mutation • BRCA1 mutation + ATM mutation","tags":["BRCA1 • BRCA2 • HRD"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA2 mutation • BRCA1 mutation • HRD • ATM mutation • HRD + BRCA1 mutation • BRCA1 mutation + ATM mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rubraca (rucaparib)"],"overall_status":"Completed","enrollment":" Enrollment 277","initiation":"Initiation: 02/15/2017","start_date":" 02/15/2017","primary_txt":" Primary completion: 07/18/2021","primary_completion_date":" 07/18/2021","study_txt":" Completion: 07/27/2021","study_completion_date":" 07/27/2021","last_update_posted":"2023-06-09"},{"id":"bc25f50b-2294-4691-b65f-1fbb1ad54d10","acronym":"","url":"https://clinicaltrials.gov/study/NCT05116579","created_at":"2021-11-12T00:10:02.444Z","updated_at":"2024-07-02T16:36:20.820Z","phase":"","brief_title":"Circulating Tumor DNA (ctDNA) Monitoring in the Assessment and Prediction of the Efficacy of PARP Inhibitors (PARPi)","source_id_and_acronym":"NCT05116579","lead_sponsor":"Sun Yat-sen University","biomarkers":" BRCA1 • BRCA2 • CDK12 • CHEK2 • RAD51B • BRIP1 • RAD51C • RAD51D • CHEK1 • BARD1 • RAD54L • FANCL • PPP2R2A","pipe":" | ","alterations":" BRCA2 mutation • BRCA1 mutation • ATM mutation • PALB2 mutation • CDK12 mutation • CHEK2 mutation • BRIP1 mutation • RAD51C mutation • RAD51D mutation • RAD51B mutation • BARD1 mutation • CHEK1 mutation • RAD54L mutation • BRCA1 mutation + ATM mutation • CHEK1 expression","tags":["BRCA1 • BRCA2 • CDK12 • CHEK2 • RAD51B • BRIP1 • RAD51C • RAD51D • CHEK1 • BARD1 • RAD54L • FANCL • PPP2R2A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA2 mutation • BRCA1 mutation • ATM mutation • PALB2 mutation • CDK12 mutation • CHEK2 mutation • BRIP1 mutation • RAD51C mutation • RAD51D mutation • RAD51B mutation • BARD1 mutation • CHEK1 mutation • RAD54L mutation • BRCA1 mutation + ATM mutation • CHEK1 expression"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 10/31/2021","start_date":" 10/31/2021","primary_txt":" Primary completion: 03/31/2023","primary_completion_date":" 03/31/2023","study_txt":" Completion: 08/31/2023","study_completion_date":" 08/31/2023","last_update_posted":"2021-11-11"}]